HMGXB3

Summary

HMGXB3 (HMG-box containing 3, HGNC:28982) is a protein-coding gene on chromosome 5q32, encoding HMG domain-containing protein 3 (Q12766).

This gene is one of the non-canonical high mobility group (HMG) genes. The encoded protein contains an HMG-box domain found in DNA binding proteins such as transcription factors and chromosomal proteins.

Source: NCBI Gene 22993 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 207 total
• MANE Select transcript: NM_014983

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28982
Approved symbol	HMGXB3
Name	HMG-box containing 3
Location	5q32
Locus type	gene with protein product
Status	Approved
Aliases	SMF, KIAA0194
Ensembl gene	ENSG00000113716
Ensembl biotype	protein_coding
OMIM	619800
Entrez	22993

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 16 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000502717, ENST00000503427, ENST00000510472, ENST00000513318, ENST00000514469, ENST00000613459, ENST00000880044, ENST00000880045, ENST00000880046, ENST00000880047, ENST00000880048, ENST00000933326, ENST00000971014, ENST00000971015, ENST00000971016, ENST00000971017, ENST00000971018, ENST00000971019, ENST00000971020

RefSeq mRNA: 2 — MANE Select: NM_014983 NM_001366501, NM_014983

CCDS: CCDS54935

Canonical transcript exons

ENST00000502717 — 20 exons

Exon	Start	End
ENSE00000767100	150037400	150037527
ENSE00000767101	150036636	150036937
ENSE00000767103	150030741	150030839
ENSE00000767104	150027020	150027117
ENSE00000767105	150026706	150026881
ENSE00000767106	150024262	150024680
ENSE00000767107	150018566	150018697
ENSE00000767108	150012255	150012353
ENSE00000767109	150010111	150010608
ENSE00000767110	150006473	150006647
ENSE00001023069	150050252	150050461
ENSE00002046422	150000739	150001179
ENSE00002235087	150004851	150004989
ENSE00003490184	150040748	150040879
ENSE00003499114	150048569	150048685
ENSE00003504662	150032454	150032603
ENSE00003540711	150047624	150047757
ENSE00003634785	150041785	150041969
ENSE00003666956	150045466	150045685
ENSE00003847800	150051725	150053128

Expression profiles

Bgee: expression breadth ubiquitous, 283 present calls, max score 97.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.8939 / max 220.2426, expressed in 1821 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
59408	30.8939	1821

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
olfactory bulb	UBERON:0002264	97.25	silver quality
type B pancreatic cell	CL:0000169	95.51	silver quality
stromal cell of endometrium	CL:0002255	95.08	gold quality
right uterine tube	UBERON:0001302	93.06	gold quality
vena cava	UBERON:0004087	91.66	gold quality
parotid gland	UBERON:0001831	91.04	gold quality
cardia of stomach	UBERON:0001162	90.95	gold quality
nasal cavity epithelium	UBERON:0005384	90.94	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.79	gold quality
diaphragm	UBERON:0001103	90.74	gold quality
pylorus	UBERON:0001166	90.29	gold quality
trachea	UBERON:0003126	90.12	gold quality
tibial nerve	UBERON:0001323	90.04	gold quality
tongue squamous epithelium	UBERON:0006919	90.03	gold quality
subthalamic nucleus	UBERON:0001906	89.90	gold quality
body of tongue	UBERON:0011876	89.82	gold quality
dorsal plus ventral thalamus	UBERON:0001897	89.79	gold quality
triceps brachii	UBERON:0001509	89.78	silver quality
right lobe of thyroid gland	UBERON:0001119	89.64	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	89.59	silver quality
inferior olivary complex	UBERON:0002127	89.52	gold quality
left lobe of thyroid gland	UBERON:0001120	89.51	gold quality
apex of heart	UBERON:0002098	89.34	gold quality
upper lobe of left lung	UBERON:0008952	89.30	gold quality
adenohypophysis	UBERON:0002196	89.24	gold quality
gluteal muscle	UBERON:0002000	88.86	silver quality
metanephros cortex	UBERON:0010533	88.85	gold quality
thyroid gland	UBERON:0002046	88.80	gold quality
right ovary	UBERON:0002118	88.79	gold quality
thymus	UBERON:0002370	88.78	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.15
E-CURD-10	no	129.44

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

59 targeting HMGXB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-6828-5P	99.31	69.21	1433
HSA-MIR-488-5P	99.28	68.12	821

Literature-anchored findings (GeneRIF, showing 2)

• Regulation of closely juxtaposed proto-oncogene c-fms and HMGXB3 gene expression by mRNA 3’ end polymorphism in breast cancer cells. (PMID:34155128)
• Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis. (PMID:34274607)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hmgxb3	ENSDARG00000077823
mus_musculus	Hmgxb3	ENSMUSG00000024622
rattus_norvegicus	Hmgxb3	ENSRNOG00000018132

Protein

Protein identifiers

HMG domain-containing protein 3 — Q12766 (reviewed: Q12766)

Alternative names: HMG box-containing protein 3, Protein SMF

All UniProt accessions (4): Q12766, A0A8C8PVR7, E9PEK0, H0YAC2

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus.

RefSeq proteins (2): NP_001353430, NP_055798* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009071	HMG_box_dom	Domain
IPR036910	HMG_box_dom_sf	Homologous_superfamily
IPR039598	HMGXB3	Family
IPR040648	HMGXB3_CxC4	Domain

Pfam: PF09011, PF18717

UniProt features (9 total): region of interest 3, compositionally biased region 3, chain 1, DNA-binding region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q12766-F1	64.21	0.32

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 99 (showing top): GCM_MYCL1, ONKEN_UVEAL_MELANOMA_UP, MORF_PML, MORF_IKBKG, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, chr5q32, MORF_RBM8A, MORF_DDX11, GCM_BNIP1, GSE13522_CTRL_VS_T_CRUZI_Y_STRAIN_INF_SKIN_IFNG_KO_DN, CREB3L4_TARGET_GENES, DIDO1_TARGET_GENES, E2F2_TARGET_GENES, GLI4_TARGET_GENES, HES4_TARGET_GENES

GO Biological Process (1): biological_process (GO:0008150)

GO Molecular Function (1): DNA binding (GO:0003677)

GO Cellular Component (2): nucleus (GO:0005634), cellular_component (GO:0005575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

414 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HMGXB3	SNRPE	P08578	616
HMGXB3	SLC26A2	P50443	589
HMGXB3	SNRPD3	P43331	513
HMGXB3	NRSN2	Q9GZP1	478
HMGXB3	NADK2	Q4G0N4	461
HMGXB3	TIGD6	Q17RP2	413
HMGXB3	DHX35	Q9H5Z1	403
HMGXB3	APOL3	O95236	370
HMGXB3	YJU2B	P13994	348
HMGXB3	PWWP2A	Q96N64	345
HMGXB3	SASS6	Q6UVJ0	343
HMGXB3	SETMAR	Q53H47	339
HMGXB3	SLC71A1	Q96MC6	330
HMGXB3	TIGD4	Q8IY51	325
HMGXB3	SLC30A9	Q6PML9	323
HMGXB3	SNRPD2	P43330	323

IntAct

9 interactions, top by confidence:

A	B	Type	Score
HMGXB3	ANXA7	psi-mi:“MI:0915”(physical association)	0.370
CDK4	HMGXB3	psi-mi:“MI:0915”(physical association)	0.370
HMGXB3	CDKN1A	psi-mi:“MI:0915”(physical association)	0.370
HMGXB3	PFDN1	psi-mi:“MI:0915”(physical association)	0.370
HMGXB3	SMN1	psi-mi:“MI:0915”(physical association)	0.370
HMGXB3	TK1	psi-mi:“MI:0915”(physical association)	0.370
APBB1	SSPOP	psi-mi:“MI:0914”(association)	0.350
DISC1	HMGXB3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): HMGXB3 (Affinity Capture-RNA), HMGXB3 (Affinity Capture-RNA), HMGXB3 (Proximity Label-MS), HMGXB3 (Two-hybrid), HMGXB3 (Two-hybrid), HMGXB3 (Two-hybrid), HMGXB3 (Two-hybrid), HMGXB3 (Two-hybrid), HMGXB3 (Two-hybrid)

ESM2 similar proteins: A0A0R4IYX6, A0A1D5NVS8, A0A1L8H0H2, A0AVK6, A5GFT6, A7XYH5, A7XYJ6, B7ZS37, B8A5Y1, D4A666, E1B7L7, E1BKK0, E1BLP6, F1LMN3, F6YVB9, F8VPJ6, Q12766, Q13029, Q14B70, Q2HNT1, Q2HNT2, Q2KHR2, Q4V9H5, Q58FA4, Q5DTH5, Q5ZIE8, Q5ZIX8, Q5ZJ69, Q5ZM88, Q63679, Q63755, Q68FE9, Q69ZF8, Q6DRC5, Q6P4F7, Q6PCM1, Q6ZSZ6, Q76L83, Q80Y19, Q8BHZ4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

207 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	173
Likely benign	10
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

3483 predictions. Top by Δscore:

Variant	Effect	Δscore
5:150004849:A:AG	acceptor_gain	1.0000
5:150004850:G:GA	acceptor_gain	1.0000
5:150004850:GCC:G	acceptor_gain	1.0000
5:150004850:GCCAT:G	acceptor_gain	1.0000
5:150006468:CTCA:C	acceptor_loss	1.0000
5:150006469:TCAG:T	acceptor_loss	1.0000
5:150006470:CAGGT:C	acceptor_loss	1.0000
5:150006472:G:GC	acceptor_loss	1.0000
5:150006633:G:GT	donor_gain	1.0000
5:150006634:A:T	donor_gain	1.0000
5:150006643:ATCCT:A	donor_gain	1.0000
5:150006644:TCCT:T	donor_gain	1.0000
5:150006645:CCT:C	donor_gain	1.0000
5:150006646:CT:C	donor_gain	1.0000
5:150006647:TGTA:T	donor_loss	1.0000
5:150006648:G:GG	donor_gain	1.0000
5:150006648:GT:G	donor_loss	1.0000
5:150006649:TAA:T	donor_loss	1.0000
5:150006652:G:GG	donor_gain	1.0000
5:150012358:GTACT:G	donor_gain	1.0000
5:150012515:GGAT:G	donor_gain	1.0000
5:150018125:G:GT	donor_gain	1.0000
5:150018126:A:T	donor_gain	1.0000
5:150024258:CTAG:C	acceptor_loss	1.0000
5:150032604:G:GG	donor_gain	1.0000
5:150037379:T:A	acceptor_gain	1.0000
5:150041783:A:AG	acceptor_gain	1.0000
5:150041784:G:A	acceptor_loss	1.0000
5:150041784:G:GA	acceptor_gain	1.0000
5:150041784:GA:G	acceptor_gain	1.0000

AlphaMissense

8407 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:150006484:T:C	L296P	1.000
5:150006489:T:G	Y298D	1.000
5:150006573:T:A	W326R	1.000
5:150006573:T:C	W326R	1.000
5:150006574:G:C	W326S	1.000
5:150006575:G:C	W326C	1.000
5:150006575:G:T	W326C	1.000
5:150006618:G:C	A341P	1.000
5:150018599:T:C	C561R	1.000
5:150018636:G:T	R573M	1.000
5:150018653:T:C	C579R	1.000
5:150032490:T:A	C870S	1.000
5:150032490:T:C	C870R	1.000
5:150032491:G:C	C870S	1.000
5:150032527:G:T	R882M	1.000
5:150032544:T:C	C888R	1.000
5:150037476:T:C	C1034R	1.000
5:150006478:C:A	A294D	0.999
5:150006480:T:G	Y295D	0.999
5:150006487:T:C	L297P	0.999
5:150006492:T:G	Y299D	0.999
5:150006554:T:A	N319K	0.999
5:150006554:T:G	N319K	0.999
5:150006562:T:A	I322N	0.999
5:150006562:T:C	I322T	0.999
5:150006562:T:G	I322S	0.999
5:150006564:A:C	S323R	0.999
5:150006566:T:A	S323R	0.999
5:150006566:T:G	S323R	0.999
5:150006583:T:C	L329P	0.999

dbSNP variants (sampled 300 via entrez): RS1000024091 (5:150038913 C>A,T), RS1000088398 (5:150037936 G>T), RS1000118570 (5:149999404 T>C), RS1000146898 (5:150015428 G>A), RS1000188063 (5:150000665 G>A), RS1000192037 (5:150043091 A>T), RS1000224117 (5:150025094 G>C), RS1000263128 (5:150030680 A>G), RS1000292105 (5:150049810 G>C), RS1000381112 (5:150044491 T>C), RS1000536110 (5:150012283 C>G), RS1000577757 (5:150041683 A>G), RS1000625537 (5:150048692 AAAT>A), RS1000661424 (5:150003440 C>G,T), RS1000679417 (5:150000241 G>A)

Disease associations

OMIM: gene MIM:619800 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	Limited	Unknown

Mondo (1): Tourette syndrome (MONDO:0007661)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST010397_24	Gut microbiota (bacterial taxa, rank normal transformation method)	1.000000e-06
GCST90002394_27	Monocyte percentage of white cells	7.000000e-16

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
GSK-J4	increases expression	1
TAK-243	increases sumoylation	1
pirinixic acid	increases activity, increases expression, affects binding	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
geraniol	increases expression	1
sodium arsenite	increases expression	1
manganese chloride	decreases expression, increases abundance	1
abrine	increases expression	1
eprenetapopt	affects expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects methylation	1
Asbestos	affects expression	1
Benzo(a)pyrene	decreases methylation	1
Doxorubicin	decreases expression	1
Manganese	decreases expression, increases abundance	1
Selenium	increases expression	1
Smoke	decreases expression	1
Dihydrotestosterone	increases expression	1
Thiram	increases expression	1
Cadmium Chloride	decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

183 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00004376	PHASE3	COMPLETED	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
NCT00206323	PHASE3	COMPLETED	A Randomized, Placebo-controlled, Tourette Syndrome Study.
NCT00206336	PHASE3	COMPLETED	An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
NCT00478842	PHASE3	COMPLETED	Pallidal Stimulation and Gilles de la Tourette Syndrome
NCT00681863	PHASE3	TERMINATED	Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
NCT01501695	PHASE3	COMPLETED	Phase III Study of 5LGr to Treat Tic Disorder
NCT03087201	PHASE3	COMPLETED	CANNAbinoids in the Treatment of TICS (CANNA-TICS)
NCT03487783	PHASE3	COMPLETED	Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette’s Syndrome
NCT03567291	PHASE3	TERMINATED	Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
NCT03571256	PHASE3	COMPLETED	A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
NCT06021522	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette’s Disorder
NCT00004393	PHASE2	COMPLETED	Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome
NCT00004652	PHASE2	COMPLETED	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome
NCT00231985	PHASE2	COMPLETED	Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
NCT00311909	PHASE2	COMPLETED	Thalamic Deep Brain Stimulation for Tourette Syndrome
NCT00529308	PHASE2	COMPLETED	Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette’s Syndrome
NCT00558467	PHASE2	COMPLETED	Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
NCT01043549	PHASE2	TERMINATED	Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
NCT01133353	PHASE2	WITHDRAWN	A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette’s Syndrome
NCT01475383	PHASE2	WITHDRAWN	Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette’s Syndrome
NCT01647269	PHASE2	COMPLETED	A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome
NCT01904773	PHASE2	COMPLETED	Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette’s Disorder
NCT02102698	PHASE2	COMPLETED	Ecopipam Treatment of Tourette’s Syndrome in Subjects 7-17 Years
NCT02217007	PHASE2	WITHDRAWN	A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02247206	PHASE2	COMPLETED	VoIP Delivered Behavior Therapy for Tourette Syndrome
NCT02581865	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
NCT02619084	PHASE2	COMPLETED	Subthalamic Stimulation in Tourette’s Syndrome
NCT02679079	PHASE2	COMPLETED	Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
NCT02879578	PHASE2	COMPLETED	Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT03066193	PHASE2	COMPLETED	Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome
NCT03247244	PHASE2	TERMINATED	Safety and Efficacy of Cannabis in Tourette Syndrome
NCT03325010	PHASE2	COMPLETED	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038	PHASE2	COMPLETED	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome